While tirzepatide is generally well-tolerated, several serious adverse effects require immediate medical attention
When liraglutide (a closely related GLP-1 agonist) was administered for just two weeks, it reduced thromboxane-induced platelet aggregation by 54% (95% CI: 18%-90%, p = 0.003)
Researchers enrolled 17,604 adults who: were 45 years or older had overweight or obesity (BMI 27) already had heart disease (such as a prior heart attack, stroke, or peripheral artery disease) did not have diabetes Participants were randomly assigned to receive either: semaglutide 2.4 mg weekly, or a placebo (an injection with no active medication) They were followed for about 40 months (over 3 years)
Among those taking GLP-1 medications for weight loss, exercise rates are decreasing, according to new research
It also helps lower cholesterol levels and may contribute to better blood pressure regulation, supporting over all well being
Cross-sectional survey of hypertension management in clinical practice in Japan: The Kanagawa Hypertension Study 2021 conducted in collaboration with Japan Medical Association Database of Clinical Medicine
